Author: Nouscom Srl

Nouscom Selected for Oral Presentation on NOUS-209 Re-treatment and Long-Term Follow-Up in Lynch Syndrome Carriers at ESMO Congress 2026

July 20, 2026
Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers

June 1, 2026

Nouscom Selected for Oral Presentation on NOUS-209 Re-treatment and Long-Term Follow-Up in Lynch Syndrome Carriers at ESMO Congress 2026